Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ARTEMIS-008
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
- NCT06498479 ↗
- Completed
- Hansoh BioMedical R&D Company
- Deep
We haven't built an HCP commentary report on ARTEMIS-008 (HS-20093 and topotecan in Small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ARTEMIS-008 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 73 | |
| Podcasts | 7 | |
| YouTube | 4 | |
| X videos | 3 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- ARTEMIS-008：A Multicenter, Randomized, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Small Cell Lung Cancer
- Interventions
- HS-20093; Topotecan
- Arms
- HS-20093 · Experimental
- Topotecan · Active comparator
- Enrollment
- 461
- Primary outcomes
- Overall survival
- Sponsor
- Hansoh BioMedical R&D Company
- Start
- Jul 4, 2024
- Primary completion
- Aug 20, 2026
- Results posted
- No
- Registry record
- NCT06498479 · updated Oct 16, 2026